SCHEMBL1854752

SCHEMBL1854752

CC(C)(C)OC(=O)N1CC[C@H]1C(=O)Nc1c(C(N)=O)oc2ccc(Br)cc12

nearest known ligand 0.47

Predicted protein targets (top 19)

geneUniProtsupporting neighboursconfidence
USP30 Q70CQ3 1/20 0.47
KMT2A Q03164 5/20 0.45
MAPT P10636 2/20 0.45
NPSR1 Q6W5P4 2/20 0.43
LMNA P02545 1/20 0.43
JAK2 O60674 1/20 0.43
ALDH1A1 P00352 4/20 0.42
TSHR P16473 3/20 0.42
KDM4E B2RXH2 3/20 0.42
HTT P42858 1/20 0.42
NPC1 O15118 2/20 0.42
RAB9A P51151 1/20 0.41
MEN1 O00255 4/20 0.41
SMN1; SMN2 Q16637 2/20 0.41
HPGD P15428 2/20 0.41
HSD17B10 Q99714 1/20 0.41
BACE1 P56817 1/20 0.40
L3MBTL1 Q9Y468 1/20 0.39
ESR1 P03372 1/20 0.38

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1851649 1.00 USP30 (0.47) USP30KMT2AMAPTNPSR1LMNA
SCHEMBL1851819 0.95 USP30 (0.53) USP30KMT2AMAPTNPSR1LMNA
SCHEMBL1850141 0.95 USP30 (0.53) USP30KMT2AMAPTNPSR1LMNA
SCHEMBL1851477 0.88 KMT2A (0.44) USP30KMT2AMAPTNPSR1JAK2
SCHEMBL1851478 0.88 KMT2A (0.44) USP30KMT2AMAPTNPSR1JAK2
SCHEMBL1852387 0.87 CYP1A2 (0.51) USP30KMT2AMAPTNPSR1ALDH1A1
SCHEMBL1852389 0.87 CYP1A2 (0.51) USP30KMT2AMAPTNPSR1ALDH1A1
SCHEMBL1859907 0.87 CYP1A2 (0.51) USP30KMT2AMAPTNPSR1ALDH1A1
SCHEMBL1851581 0.86 NPC1 (0.51) KMT2AMAPTALDH1A1TSHRKDM4E
SCHEMBL1856586 0.86 KMT2A (0.43) USP30KMT2AMAPTNPSR1ALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2097419-B1 BENZOFUROPYRIMIDINONES AS PROTEIN KINASE INHIBITORS EXELIXIS INC (US) 2011-05-25 EP disclosed
US-20090247559-A1 Benzofuropyrimidinones EXELIXIS, INC. (US) 2009-10-01 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20090247559-A1 Benzofuropyrimidinones F12, BRI3BP, BRD1 USP30 4459/4885KMT2A 2152/4885MAPT 1941/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.